Highest-materiality recent filing
CME Group adjourns four proposals due to Class B quorum shortfall; elects all director nominees
Class B-1 through B-4 failed quorum (33.3% required); only 24-33% present. Proposals 4-8 adjourned to June 9, 2026 virtual meeting.
CME Group subsidiary amends $7B clearing house credit facility
Amendment No. 11 to 364-day multi-currency revolving secured credit facility, dated April 22, 2026.
CME Group files 8-K for Q1 2026 earnings; press release exhibit not provided in input
Furnished quarterly financial results for quarter ended March 31, 2026.
Q4 2025 revenue $1.8B (+20% YoY), record full-year revenue $7.1B (+35%).
CME Group Announces Pricing Changes via Special Executive Report 9676
On February 2, 2026, CME Group communicated pricing changes to clients in Special Executive Report 9676.
CME Group Q3 2025 earnings reported; press release not provided
Exhibit 99.1 press release text missing; specific financial figures unavailable.
CME Group CAO Jack Tobin to retire; will stay through Oct 30, 2026
Jack Tobin, Managing Director and Chief Accounting Officer, notified retirement on Sept 9, 2025.
CME Group wins unanimous jury verdict in Class B shareholder lawsuit
Jury returned unanimous verdict on July 25, 2025 in favor of CME Group and CBOT.
CME Group Inc. reports financial results for quarter ended June 30, 2025
CME Group issued a press release on July 23, 2025 reporting its financial results for the quarter ended June 30, 2025.
CME Group 2025 annual meeting elects 14 directors, ratifies auditor, approves say-on-pay
All 14 equity directors elected; highest votes for Benesh (280.3M) and Lucas (280.1M); lowest for Lockett (170.0M).
CME Group enters $2.25B credit facility maturing 2030, amends $7B clearing facility
New $2.25B multi-currency revolving credit facility matures April 23, 2030; can be increased to $3.25B.
CME Group Q1 2025 earnings released; specifics not included in 8-K
CME Group disclosed Q1 2025 financial results via press release on April 23, 2025, but no revenue or EPS figures are available in this filing.
CME Group and S&P Global sell OSTTRA joint venture to KKR for $3.1B
Total enterprise value of $3.1 billion; proceeds split 50/50 between CME and S&P Global.
CME Group issues $750M 4.400% Notes due 2030 to refinance 2025 notes
Issued $750M aggregate principal of 4.400% Notes due March 15, 2030 at 99.573% of par.
CME Group issues $750M of 4.400% Notes due 2030 in public offering
Principal amount $750M at 4.400% interest, maturing 2030.
CME Group reports Q4 2024 financial results; details not available in filing text
Press release for quarter ended December 31, 2024 furnished as Exhibit 99.1.
CME Group updates Clearing House collateral fees and client pricing
Changes communicated via Advisory Notice 24-383 and Special Executive Report 9482.
CME Group declares $2.1B annual variable dividend ($5.80/share) and $3B share repurchase program
Annual variable dividend of $5.80 per share ($2.1B total) payable Jan 16, 2025 to holders of record Dec 27, 2024.
CME Group extends CEO Terry Duffy's contract to Dec 2026; appoints new President/CFO and COO
Chairman and CEO Terry Duffy's employment extended through December 31, 2026; no changes to base salary, bonus, or LTI target.
CME Group reports Q3 results; press release not fully extracted
Filing indicates Q3 2024 earnings released; press release text not included in this excerpt.
CME Group announces Q2 2024 earnings; specific figures not provided in filing text
Filed Form 8-K on July 24, 2024 with Item 2.02 for Q2 2024 results.
Mike Dennis joins as Senior Managing Director, Global Head of Fixed Income, reporting to CEO Terry Duffy.
CME Group annual meeting: all equity directors elected, Class B quorum not met
All 17 Equity Directors elected; Phyllis Lockett received 103.8M against, highest dissent.
CME subsidiary amends credit facility to $7B, eligible to increase to $10B
Amendment No. 8 to existing 364-day multi-currency credit facility executed on April 24, 2024.
CME Group reports Q1 2024 results; specific numbers unavailable from filing text
CME Group filed Q1 2024 earnings results on April 24, 2024 via Form 8-K.
the Company announced that Ms. Julie Holzrichter has decided to step down from her role as Chief Operating Officer, a position she held since 2014.
Ms. Suzanne Sprague who has served as our Senior Managing Director & Global Head of Clearing and Post-Trade Services since February 2022 has also assumed the role of Chief Operating Officer.
Ms. Lynne Fitzpatrick has been promoted to President and Chief Financial Officer.
on July 8, 2024, Mr. Dennis notified the Company of his intent to retire from the Company’s Board of Directors, effective immediately.
Michael G. Dennis will be joining CME Group Inc. (the “CME Group” or the “Company”) as of August 5, 2024 in the role of Senior Managing Director Global Head, Fixed Income.
Max materiality 0.85 · Median 0.50 · Most common event earnings